UNIVERSI
TÄ
TS-
BIBLIOTHEK
P
ADERBORN
Anmelden
Menü
Menü
Start
Hilfe
Blog
Weitere Dienste
Neuerwerbungslisten
Fachsystematik Bücher
Erwerbungsvorschlag
Bestellung aus dem Magazin
Fernleihe
Einstellungen
Sprache
Deutsch
Deutsch
Englisch
Farbschema
Hell
Dunkel
Automatisch
Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist
gegebenenfalls
nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Universitätsbibliothek
Katalog
Suche
Details
Zur Ergebnisliste
Ergebnis 14 von 15
Datensatz exportieren als...
BibTeX
Phase II study of ifosfamide in childhood brain tumors: A report by the French society of pediatric oncology (SFOP)
Medical and pediatric oncology, 1993, Vol.21 (1), p.49-53
Chastagner, Pascal
Sommelet-Olive, Danièle
Kalifa, Chantal
Brunat-Mentigny, Maud
Zucker, Jean-Michel
Demeocq, François
Baranzelli, Marie-Christine
Tron, Philippe
Bergeron, Christophe
Pein, François
De Lumley, Lionel
1993
Volltextzugriff (PDF)
Details
Autor(en) / Beteiligte
Chastagner, Pascal
Sommelet-Olive, Danièle
Kalifa, Chantal
Brunat-Mentigny, Maud
Zucker, Jean-Michel
Demeocq, François
Baranzelli, Marie-Christine
Tron, Philippe
Bergeron, Christophe
Pein, François
De Lumley, Lionel
Titel
Phase II study of ifosfamide in childhood brain tumors: A report by the French society of pediatric oncology (SFOP)
Ist Teil von
Medical and pediatric oncology, 1993, Vol.21 (1), p.49-53
Ort / Verlag
New York: Wiley Subscription Services, Inc., A Wiley Company
Erscheinungsjahr
1993
Quelle
Wiley Online Library Journals Frontfile Complete
Beschreibungen/Notizen
Forty‐two evaluable pediatric patients with a variety of recurrent primary brain tumors participated in a phase II ifosfamide trial. Their mean age was 10 years. All patients were treated with ifosfamide, 3 g/m2/day for 2 days every 2 weeks. Response was assessed on clinical and radiological criteria after at least 2 courses of therapy. The overall response rate was 12% (5/42). One complete and 2 partial responses were documented in 21 patients with medulloblastoma. A partial response was demonstrated in 1 patient with primitive neurectodermal tumor (PNET) and in 1 patient with ependymoma. No activity was observed in astrocytic tumors. Toxicity was primarily neurologic (16 out of 54 patients, 30%). Hematological toxicity, without severe morbidity, was encountered in 9% of courses (16/179). Ifosfamide, administered at this dose regimen has modest efficacy in the treatment of recurrent childhood medulloblastoma and ependymoma and appears inactive for gliomas. Further trials with other dose schedules are necessary to assess the activity of this drug. However, according to the neurotoxicity observed in our trial, we would not recommend building a protocol using ifosfamide for highly progressive brain tumors. © 1993 Wiley‐Liss, Inc.
Sprache
Englisch
Identifikatoren
ISSN: 0098-1532
eISSN: 1096-911X
DOI: 10.1002/mpo.2950210110
Titel-ID: cdi_crossref_primary_10_1002_mpo_2950210110
Format
–
Schlagworte
Adolescent
,
Adult
,
Brain Neoplasms - drug therapy
,
Child
,
Child, Preschool
,
ependymoma
,
Female
,
Humans
,
Ifosfamide - adverse effects
,
Ifosfamide - therapeutic use
,
Infant
,
Male
,
medulloblastoma
,
Neoplasms, Nerve Tissue - drug therapy
,
PNET
,
primitive neuroectodermal tumors
,
recurrent primary brain tumors
,
Treatment Outcome
Weiterführende Literatur
Empfehlungen zum selben Thema automatisch vorgeschlagen von
bX